CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,743,000	$ 1,068,000
Accounts receivable	14,000	44,000
Total current assets	2,757,000	1,112,000
Investments	2,000	2,000
Property and equipment, net	152,000	165,000
Assets received in settlement agreement	5,550,000	5,724,000
Intellectual property, net	590,000	630,000
Other asset	2,000	2,000
Total assets	9,053,000	7,635,000
Current liabilities
Accounts payable and accrued expenses	1,572,000	1,335,000
Accrued expenses - related parties	105,000	105,000
Note payable to related party	340,000	275,000
Total current liabilities	2,017,000	1,715,000
Long-term liabilities
Convertible notes payable, net	204,000	2,139,000
Total long-term liabilities	204,000	2,139,000
Total liabilities	2,221,000	3,854,000
STOCKHOLDERS EQUITY
Capital stock $.001 par value Preferred, authorized 1,000,000 shares
Common, authorized 950,000,000 shares, 533,781,064 shares issued, and outstanding, respectively	534,000	534,000
Additional paid-in-capital	68,232,000	63,527,000
Accumulated deficit	(60,087,000)	(61,338,000)
Total Manhattan Scientifics, Inc. stockholders' equity	8,679,000	2,723,000
Noncontrolling interest	(2,905,000)
Total stockholders' equity	5,774,000	2,723,000
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	9,053,000	7,635,000
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS EQUITY
Capital stock $.001 par value Preferred, authorized 1,000,000 shares
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS EQUITY
Capital stock $.001 par value Preferred, authorized 1,000,000 shares
Series C Redeemable Preferred Stock [Member]
STOCKHOLDERS EQUITY
Capital stock $.001 par value Preferred, authorized 1,000,000 shares
Mezzanine Equity Series D Convertible Preferred Stock [Member]
Mezzanine equity
Mezzanine equity Series D convertible preferred	$ 1,058,000	$ 1,058,000